News
BCDA
2.260
+5.61%
0.120
BioCardia’s Earnings Call Highlights Strong Trial Results
TipRanks · 19h ago
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), BioCardia (BCDA) and Guardian Pharmacy Services, Inc. Class A (GRDN)
TipRanks · 1d ago
Biocardia highlights promising CardiAMP-HF trial data with reduced mortality and improved quality of life
Seeking Alpha · 1d ago
BioCardia Clarifies Timing for CardiAMP-HF Results Call
TipRanks · 2d ago
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
Barchart · 2d ago
BioCardia Reports Positive Phase 3 CardiAMP-HF Results
TipRanks · 2d ago
BioCardia’s CardiAMP-HF trial primary endpoint did not reach significance
TipRanks · 2d ago
BIOCARDIA PHASE 3 CARDIAMP-HF TRIAL OF NOVEL CARDIAC CELL THERAPY FOR ISCHEMIC HEART FAILURE SHOWS INCREASED SURVIVAL, DECREASED CARDIAC EVENTS, AND IMPROVED QUALITY OF LIFE AT TWO YEARS
Reuters · 2d ago
Weekly Report: what happened at BCDA last week (0324-0328)?
Weekly Report · 2d ago
BIOCARDIA REPORTS 2024 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS
Reuters · 6d ago
Weekly Report: what happened at BCDA last week (0317-0321)?
Weekly Report · 03/24 11:14
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
Barchart · 03/21 07:30
Weekly Report: what happened at BCDA last week (0310-0314)?
Weekly Report · 03/17 11:25
Weekly Report: what happened at BCDA last week (0303-0307)?
Weekly Report · 03/10 11:27
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System
Barchart · 03/10 08:15
Director’s Bold Move: Major Stock Purchase Signals Confidence in BioCardia
TipRanks · 03/06 02:15
Weekly Report: what happened at BCDA last week (0224-0228)?
Weekly Report · 03/03 11:26
BioCardia finishes data freezing in heart failure therapy study for presentation
TipRanks · 02/27 14:20
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions
Barchart · 02/27 08:15
Weekly Report: what happened at BCDA last week (0217-0221)?
Weekly Report · 02/24 11:26
More
Webull provides a variety of real-time BCDA stock news. You can receive the latest news about Biocardia Inc through multiple platforms. This information may help you make smarter investment decisions.
About BCDA
More
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.